The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Common shares and common share purchase warrants in Canopy Growth
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
Berger Group Holdings, Inc.
Advised Berger Group Holdings, Inc. (“Louis Berger”), a leading international professional services engineering firm, on its sale to WSP Global Inc.
Tri-Dim Filter Corporation
Advised Mann+Hummel, a leading global filtration company, on the acquisition of Tri-Dim Filter Corporation, the single largest privately-held air filtration company in North America
Babcock & Wilcox Inc.’s industrial environmental technology business
Advised Dürr AG, a German mechanical and plant engineering company, on the acquisition of Babcock & Wilcox’s industrial environmental technology business (MEGTEC and Universal)
Aventics GmbH
Advised Emerson Electric Co., a diversified global technology and industrial company, on the acquisition of Aventics GmbH, a leading designer and manufacturer of pneumatic devices and systems
Sika
Advised Cascade Investments LLC and Bill & Melinda Gates Foundation Trust on the resistance to the sale of the Burkard Family’s controlling stake in Sika AG (17% of capital equivalent to 53% of voting rights) to Compagnie de Saint-Gobain
The Alpha Corporation (AOC Resins)
Advised AOC Resins, a leading global producer of polyester and vinyl ester resins, gel coats, colorants dispersions and specialty additives for composites and cast polymer applications, on its sale to CVC Capital Partners
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Grupo Proenfar
Advised Grupo Proenfar, a Colombia-based plastics packaging solutions provider, and its shareholders on its sale to Weener Plastics
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
Crem International
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
Faster S.p.A.
Advised Capvis Equity Partners on the sale of its portfolio company Faster Group, a producer of quick-release hydraulic couplings, to Sun Hydraulics
CB&I
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
36.5% stake in DNV GL Group AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
B-G Mechanical Contractors, Inc., B-G Mechanical Services, Inc., Elmsford Sheet Metal Works, Inc., Fred Williams, Inc., H.T. Lyons, Inc. and TryState Mechanical, Inc.
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of six subsidiaries, within its Mechanical Services business, to Engie North America
Morris Corporation
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
Thermamax
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Valves & Controls Business of Pentair
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
Aegerion Pharmaceuticals
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization